Food and Drug Administration

CFA and Center for Science in the Public Interest Tell Congress to Let FDA Determine the Safety of Cannabidiol (CBD) Products

In response to proposed legislative language in the Senate that would direct FDA to exercise “enforcement discretion” with respect to certain CBD products, CFA and the Center for Science in the Public Interest sent the following letter urging Senators to let FDA do its job. The letter points out that many clinical trials have called into question the safety of CBD, particularly when consumed by children. High potency CBD products, including products marketed for children, are currently available for sale. The proposed legislation would give FDA a narrow window of time in which to declare such products unsafe, undermining federal regulators’ ability to protect the public.

CBD Letter